Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) but lowers the price target from $77 to $66.
August 02, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Apellis Pharmaceuticals but lowers the price target from $77 to $66.
The Buy rating suggests continued confidence in Apellis Pharmaceuticals' long-term prospects, but the lowered price target indicates some caution about short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100